Clinical Trial Update: A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

View source ↗

Summary

A study to evaluate real-world use and outcomes of TAR-200 for non-muscle-invasive bladder cancer in the United States is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• TAR-200

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Non-Muscle Invasive Bladder Neoplasms | Status: RECRUITING